Evidence map›Paper›PMID 35810317›Full record

ArticleAIDS research and therapy2022

Virological outcomes and risk factors for non-suppression for routine and repeat viral load testing after enhanced adherence counselling during viral load testing scale-up in Zimbabwe: analytic cross-sectional study using laboratory data from 2014 to 2018.

Trudy Tholakele Mhlanga, Bart K M Jacobs, Tom Decroo, Emma Govere, Hilda Bara, Prosper Chonzi, Ngwarai Sithole, Tsitsi Apollo, Wim Van Damme, Simbarashe Rusakaniko and 2 more

Open access · goldAbstract read
In one paragraph

Article in AIDS research and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Trudy Tholakele Mhlanga *Institute of Tropical Medicine, Antwerp, Belgium.
Bart K M JacobsInstitute of Tropical Medicine, Antwerp, Belgium.
Tom DecrooInstitute of Tropical Medicine, Antwerp, Belgium.
Emma GovereHarare City Council, Department of Health, Harare, Zimbabwe.
Hilda BaraHarare City Council, Department of Health, Harare, Zimbabwe.
Prosper ChonziHarare City Council, Department of Health, Harare, Zimbabwe.
Ngwarai SitholeAIDS & TB Unit, Ministry of Health & Child Care, Harare, Zimbabwe.
Tsitsi ApolloAIDS & TB Unit, Ministry of Health & Child Care, Harare, Zimbabwe.
Wim Van DammeInstitute of Tropical Medicine, Antwerp, Belgium.
Simbarashe RusakanikoFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Lutgarde LynenInstitute of Tropical Medicine, Antwerp, Belgium.
Richard Makurumidze *Institute of Tropical Medicine, Antwerp, Belgium. rmakurumidze@ext.itg.be.
Instituut voor Tropische Geneeskunde · BEMinistry of Health and Child Welfare · ZWVrije Universiteit Brussel · BEUniversity of Zimbabwe · ZW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince the scale-up of routine viral load (VL) testing started in 2016, there is limited evidence on VL suppression rates under programmatic settings and groups at risk of non-suppression. We conducted a study to estimate VL non-suppression (> 1000 copies/ml) and its risk factors using "routine" and "repeat after enhanced adherence counselling (EAC)" VL results.

methodsWe conducted an analytic cross-sectional study using secondary VL testing data collected between 2014 and 2018 from a centrally located laboratory. We analysed data from routine tests and repeat tests after an individual received EAC. Our outcome was viral load non-suppression. Bivariable and multivariable logistic regression was performed to identify factors associated with having VL non-suppression for routine and repeat VL.

resultsWe analysed 103,609 VL test results (101,725 routine and 1884 repeat test results) collected from the country's ten provinces. Of the 101,725 routine and 1884 repeat VL tests, 13.8% and 52.9% were non-suppressed, respectively. Only one in seven (1:7) of the non-suppressed routine VL tests had a repeat test after EAC. For routine VL tests; males (vs females, adjusted odds ratio (aOR) = 1.19, [95% CI 1.14-1.24]) and adolescents (10-19 years) (vs adults (25-49 years), aOR = 3.11, [95% CI 2.9-3.31]) were more at risk of VL non-suppression. The patients who received care at the secondary level (vs primary, aOR = 1.21, [95% CI 1.17-1.26]) and tertiary level (vs primary, aOR = 1.63, [95% CI 1.44-1.85]) had a higher risk of VL non-suppression compared to the primary level. Those that started ART in 2014-2015 (vs < 2010, aOR = 0.83, [95% CI 0.79-0.88]) and from 2016 onwards (vs < 2010, aOR = 0.84, [95% CI 0.79-0.89]) had a lower risk of VL non-suppression. For repeat VL tests; young adults (20-24 years) (vs adults (25-49 years), (aOR) = 3.48, [95% CI 2.16 -5.83]), adolescents (10-19 years) (vs adults (25-49 years), aOR = 2.76, [95% CI 2.11-3.72]) and children (0-9 years) (vs adults (25-49 years), aOR = 1.51, [95% CI 1.03-2.22]) were at risk of VL non-suppression.

conclusionClose to 90% suppression in routine VL shows that Zimbabwe is on track to reach the third UNAIDS target. Strategies to improve the identification of clients with high routine VL results for repeating testing after EAC and ART adherence in subpopulations (men, adolescents and young adolescents) at risk of viral non-suppression should be prioritised.

Indexed as

Anti-HIV AgentsHIV InfectionsAdolescentChildCounselingCross-Sectional StudiesFemaleHumansMaleRisk FactorsViral LoadYoung AdultZimbabweAnti-HIV AgentsARTHIV viral load testingImplementationViral load non-suppressionZimbabwe

Identifiers

PMID35810317
PMCPMC9270749
OpenAlexW4284989842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.